Last reviewed · How we verify
NCT06854185
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
NA trial testing Paso Program in Metabolic Dysfunction Associated Steatotic Liver Disease in 50 participants. Participants enrolled and being followed up; not accepting new ones.
5 February 2026
Quick facts
| Lead sponsor | Baylor College of Medicine |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 5 February 2025 |
| Primary completion | 5 February 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Paso Program
Conditions studied
- Metabolic Dysfunction Associated Steatotic Liver Disease — all drugs for Metabolic Dysfunction Associated Steatotic Liver Disease →
- Overweight (BMI > 25) — all drugs for Overweight (BMI > 25) →
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
Baylor College of Medicine
Who can join
Adults 18 to 70, any sex, with Metabolic Dysfunction Associated Steatotic Liver Disease or Overweight (BMI > 25). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn whether the Paso weight loss program is feasible for Mexican and Central American patients with fatty liver disease. In addition, the investigators will also look at whether the program improves weight loss, fatty liver disease, physical activity, diet, and family support among patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06854185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Dysfunction Associated Steatotic Liver Disease
Currently open trials in the same condition.
- NCT06935994 — Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease · Phase 2 · recruiting
- NCT06490432 — Pattern of Cardiac Arrhythmia in Patients With MASLD · recruiting
Other Baylor College of Medicine trials
Trials by the same sponsor.
- NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
- NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
- NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
- NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
- NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06854185 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06854185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing